Lorundrostat Beneficial for BP Reduction in Uncontrolled Hypertension
By Elana Gotkine HealthDay Reporter
WEDNESDAY, April 30, 2025 -- For patients with uncontrolled and treatment-resistant hypertension, lorundrostat is associated with greater reductions in blood pressure than placebo, according to a study published online April 23 in the New England Journal of Medicine.
Luke J. Laffin, M.D., from the Cleveland Clinic Foundation, and colleagues conducted a double-blind, randomized trial involving patients who were receiving two to five antihypertensive medications and had a blood pressure measurement of 140/90 mm Hg or higher obtained during an office visit. Participants underwent a standardized antihypertensive regimen for three weeks; those with an average 24-hour ambulatory blood pressure of 130/80 mm Hg or higher were randomly assigned to receive placebo, lorundrostat (50 mg daily; stable-dose group), or lorundrostat starting at 50 mg daily and increasing to 100 mg daily if systolic blood pressure was ≥130 mm Hg after four weeks (dose-adjustment group).
Two hundred eighty-five patients were randomly assigned: 94, 96, and 95 to the stable-dose group, dose-adjustment group, and placebo group, respectively. The researchers found that after 12 weeks, the least-squares mean change in 24-hour average systolic blood pressure was –15.4, –13.9, and –7.4 mm Hg in the stable-dose, dose-adjustment, and placebo groups, respectively. The placebo-adjusted change in blood pressure was –7.9 and –6.5 mm Hg in the stable-dose and dose-adjustment groups, respectively. In the combined lorundrostat groups, the placebo-adjusted change in 24-hour average systolic blood pressure from baseline to week 4 was –5.3 mm Hg.
"Aldosterone synthase inhibition with lorundrostat effectively lowered blood pressure in patients with uncontrolled and treatment-resistant hypertension," the authors write.
Several authors disclosed ties to biopharmaceutical, medical device, and medical technology companies, including Mineralys Therapeutics, which is developing lorundrostat and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Increasing Proportion of U.S. Adults Unaware They Have Hypertension
MONDAY, June 9, 2025 -- From 2013 to 2023, there was an increase in the proportion of U.S. adults who were unaware of having hypertension, according to a research letter published...
Preoperative Blood Pressure Strategies Yield Similar Postoperative Cognitive Results
FRIDAY, June 6, 2025 -- For patients undergoing noncardiac surgery, neurocognitive outcomes do not differ with hypotension-avoidance and hypertension-avoidance strategies...
Concurrent Hypertension + Type 2 Diabetes Predict High Mortality Risk
WEDNESDAY, June 4, 2025 -- Adults with concurrent hypertension and type 2 diabetes (T2D) have high mortality risk compared with those who have neither condition or only one...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.